References
  1. World Health Organization. WHO Coronavirus (COVID-19) dashboard. Accessed on 6 June 2022. https://covid19.who.int/
  2. Araf Y, Akter F, Tang Y, et al. Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current Covid‐19 Vaccines. J Med Virol . 2022;94(5):1825-1832.
  3. Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in Tshwane, South Africa. Int J Infect Dis . 2022;116:38-42.
  4. Sigal A. Milder disease with Omicron: Is it the virus or the pre-existing immunity? Nat Rev Immunol . 2022;22(2):69-71.
  5. Lim HJ, Jung HS, Park MY, Baek YH, Kannappan B, Park JY, Yang JH, Seol JH, Lee MW, et al. Evaluation of three automated extraction systems for the detection of SARS-CoV-2 from clinical respiratory specimens.Life . 2022;12(1):68.
  6. Kumar S, Lomash A, Faruq M, et al. Amplicon-based nanopore minion sequencing of patients with COVID-19 omicron variant from India. medRxiv; 2021. Published online 30 December 2021.
  7. Ledford H. How severe are omicron infections? Nature . 2021;600(7890):577-578.
  8. Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of Omicron and Delta variant dominance: A prospective observational study from the Zoe Covid Study. Lancet . 2022;399(10335):1618-1624.
  9. Greaney AJ, Starr TN, Gilchuk P, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2021;29:44–57.
  10. Kim M-K, Lee B, Choi YY, et al. Clinical characteristics of 40 patients infected with the SARS-CoV-2 omicron variant in Korea.J Korean Med Sci. 2022;37:e31.
  11. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves.JAMA . 2022;327:583–84.
  12. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study. Lancet . 2022;399(10332):1303-12.
  13. Covid-19 vaccination in India. Wikipedia. Accessed December 14, 2022. https://en.wikipedia.org/wiki/COVID-19_vaccination_in_India.
  14. Thomas A.L., Alarcon P.C., Divanovic S., Chougnet C.A., Hildeman D.A., Moreno-Fernandez M.E. Implications of inflammatory states on dysfunctional immune responses in aging and obesity. Front Aging.  2021;2(42).
  15. Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system.Front Immunol . 2020;11:1582.
  16. Fourati S., Cristescu R., Loboda A., Talla A., Filali A., Railkar R., et al. Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination. Nat Commun.  2016;7(1):1-2.
  17. Iyonaga T., Shinohara K., Mastuura T., Hirooka Y., Tsutsui H. Brain perivascular macrophages contribute to the development of hypertension in stroke-prone spontaneously hypertensive rats via sympathetic activation. Hypertens Res.  2020;43(2):99–110.
  18. Soegiarto G, Wulandari L, Purnomosari D, Fahmita KD, Gautama HI, Hadmoko ST, Prasetyo ME, Mahdi BA, et al. Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2.Vaccine. 2022;40(30):4046-4056.
  19. Boroumand AB, Forouhi M, Karimi F, Moghadam AS, Naeini LG, Kokabian P, Naderi D. Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review. Front Immunol . 2022;13:940357.
  20. Ahmad Malik J, Ahmed S, Shinde M, et al. The impact of covid-19 on Comorbidities: A review of recent updates for combating it.Saudi J Biol Sci . 2022;29(5):3586-3599.
  21. Lippi G, Wong J, Henry BM. Hypertension and its severity or mortality in coronavirus disease 2019 (covid-19): A pooled analysis.Polish Arch Intern Med . 2020;130:304-309.
  22. Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, Knighton P, Holman N, Khunti K, Sattar N, et al. Associations of Type 1 and Type 2 Diabetes with COVID-19-Related Mortality in England: A Whole-Population Study. Lancet Diabetes Endocrinol . 2020;8;813–822.
  23. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet . 2020;395(10228):e52.
  24. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev . 2020;e3319.
  25. The GISAID initiative. GISAID—hCov19 variants. Accessed June 12, 2022. https://www. gisaid.org/hcov19-variants.
  26. Hui KP, Ho JC, Cheung M, et al. SARS-CoV-2 omicron variant replication in human Bronchus and lung ex vivo. Nature . 2022;603(7902):715-720.
  27. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843-1844.
  28. Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, Tan Y, Wang H, Wang C, Liu L, Liu Y. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun . 2021;12(1):1-9.
  29. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet 2022; 399: 437–46.
  30. Zhang J, Dong X, Cao Y, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy . 2020;75(7):1730-1741.
  31. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with covid-19 in Wuhan, China: A retrospective cohort study. Lancet . 2020;395(10229):1054-1062.
  32. Liu W, Tao ZW, Lei W, et al. Analysis of factors associated with disease outcomes in hospitalised patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020;133(9):1032-1038.
  33. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med.  2020;382(18):1708-1720.
  34. Vardavas C, Nikitara K. Covid-19 and smoking: A systematic review of the evidence. Tob Induc Dis . 2020;18:20.
  35. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). In: StatPearls . Treasure Island (FL): StatPearls Publishing; October 13, 2022
  36. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis . 2020;20(7):773.